CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Brazil will break the patent on Abbott Laboratories' protease inhibitor Kaletra and begin making generic versions of the drug unless Abbott lowers the price of the pill by 42% within 10 days, health officials announced Friday. Brazilian health minister Humberto Costa informed Abbott that the company must lower the cost of the drug to $1.17 per pill. A generic version of the drug made by Brazilian state-run laboratory Farmanguinhos would cost only 68 cents per pill, according to Costa. The country would break the patent under national and international laws that allow generic versions of patented drugs to be made during periods of national emergencies. If the patent is broken, it would be mark the first time any government has broken one on an HIV antiretroviral drug and the first time Brazil broken a patent on any medication. Abbott says the nation does not have a legal basis to break the patent on Kaletra and says the company already sells it at the lowest price outside of Africa. "A compulsory license is not in the best interest of Brazilian patients because it puts the government's desire to cut health care spending ahead of patients' need for new and better treatments," Abbott said in a press release. The company did not say how it planned to respond to Brazil's announcement. Brazil is currently negotiating for price reductions on Merck's Sustiva and Gilead Science's Viread. The country already makes several generic versions of anti-HIV drugs, which it provides for free to its HIV-positive citizens through the nation's highly touted HIV prevention and treatment program. U.S. AIDS advocates praised the decision by Brazilian officials to break patents on anti-HIV drugs that pharmaceutical companies will not steeply discount. "The medicines are critical for HIV treatment when initial combinations of medicine have failed," said Asia Russell of Health Global Access Project. "The high cost of second generation patented HIV/AIDS drugs threatens the sustainability of treatment programs not only in Brazil but throughout the developing world. Now other countries, particularly countries with the capacity to produce and export medicines to other countries, must follow suit and break the patent monopolies of overpriced AIDS drugs in order to ensure access to affordable lifelong treatment."
From our Sponsors
Most Popular
18 of the most batsh*t things N.C. Republican governor candidate Mark Robinson has said
October 30 2024 11:06 AM
True
After 20 years, and after tonight, Obama will no longer be the Democrats' top star
August 20 2024 12:28 PM
Trump ally Laura Loomer goes after Lindsey Graham: ‘We all know you’re gay’
September 13 2024 2:28 PM
60 wild photos from Folsom Street East that prove New York City knows how to play
June 21 2024 12:25 PM
Melania Trump cashed six-figure check to speak to gay Republicans at Mar-a-Lago
August 16 2024 5:57 PM
Transgender 18-year-old Jazlynn Johnson shot to death in Las Vegas
May 14 2024 2:08 PM
Latest Stories
Who is Susie Wiles, Donald Trump's pick for White House chief of staff?
November 07 2024 9:25 PM
Jamie Lee Curtis sends love and support to LGBTQ+ folks, allies, and others post-election
November 07 2024 6:20 PM
Yes, Republicans who vowed retribution are now admitting Project 2025 is real
November 07 2024 6:13 PM
Spate of racist text messages goes out after Trump's election
November 07 2024 6:09 PM
We elect presidents that reflect who we are, and in Trump, America proves to be inherently selfish
November 07 2024 5:53 PM